Valuation dashboard for ProQR Therapeutics N.V. (PRQR) with P/E N/A, P/B 2.09, EV/EBITDA -2.27 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10).
Analysis Summary
ProQR Therapeutics N.V. reported revenue of $15.3M in the most recent fiscal year, growing at a 5-year CAGR of 71.5%.
Trailing-twelve-month margins: gross margin 92.3%, operating margin -232.7%, net margin -228.3%.
At the current price of $1.86, PRQR has negative trailing earnings (P/E not meaningful) and an ROE of -68.44%. Market capitalisation stands at $196M.
Balance sheet quality for PRQR: current ratio of 3.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.09 |
| EV / EBITDA | -2.27 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-38.77 |
| vs Current Price | -2184.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V. | $196M | 2.09 | -68.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.86 |
| Market Cap | $196M |
| Exchange | NASDAQ |
| Country | NL |
Profitability
| Return on Equity | -68.44% |
| Return on Invested Capital | -41.91% |
| Return on Assets | -31.76% |
| Gross Margin | 92.33% |
| Operating Margin | -232.71% |
| Net Margin | -228.29% |
Related companies: ACHV · ALLO · ARCT · CAPR · EDIT · IMMP · MREO
Explore sector: Healthcare · Biotechnology
More sections of PRQR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks